16×1	28								/08 (2/92) eet 1 of 2	
OCT 1 9 1009 Form PTO-1449			Attorney's Docket No. GNE-0290.041		Application Serial No. 10/617,573					
INFORMATION DISCLOSURE STATEMENT					Applicant(s) Ellen FILVAROFF, et al.					
(use several sheets if necessary)				Filing Date: Group Art Unit: JULY 11, 2003 1646						
				U.S	. PATENT DOCUMENTS					
Examiner Initials	Ref. No.	Date	Document No.	Name Class Subcla			Subclass	s Filing Date (if appropriate)		
	1.	03/28/2000	6,043,344	Jac	cobs, et al.					
	2.	03/13/2003	2003/0049255	Sims, et al.						
	l. –		F	ÖRE	IGN PATENT DOCUMENTS	<u> </u>				
Examiner Initials	Examiner Ref. Date Document No. N		Na		Class	Subclass	Transl YES	ation NO		
	3.	07/13/1995	WO 95/18826	PC	T	1				
	4.	02/06/1997	WO 97/04097	PC		<u> </u>	-			
	5.	01/18/2001	WO 01/04304	PC		 				
	6.	03/08/2001	WO 01/16318	PC						
	7.	06/28/2001	WO 01/46420	PC						
*	8.	09/20/2001	WO 01/68848	PC					<u> </u>	
- 7	9.	11/29/2001	WO 01/90358	PC			 			
	10.	01/03/2002	WO 02/00690	PC		<u> </u>	<u> </u>			
*	11.	01/31/2002	WO 02/08284	PC						
	12.	05/21/2004	WO 2004/042009	PC	T					
	13.	01/06/2005	WO 2005/000897	PC	T				-	
···	14.	02/03/2005	WO 2005/010044	PC	T				<u> </u>	
	l	,	·		OTHER DOCUMENTS	-1,	<u> </u>	1		
			(includin	g aut	hor, title, date, pertinent pages, etc.)					
Examiner	Ref.	Title								
Initials	No.									
	15.	1.	Product Data Sheet							
	16. 17.	1 4	"qk39g09.x1 NCI_CGAP_Co8 Homo sapiens cDNA clone Image:1871392 3', mRNA sequence." XP002154807, (1998)							
	18.		Aggarwal, S., et al., The Journal of Biological Chemistry – <u>278(3)</u> :1910-1914 (2003) Aggarwal, S., et al., Journal of Leukocyte Biology – <u>71:1-8</u> (2002)							
	19.		Becher, B., et al., The Journal of Clinical Investigation – 112(8):1186-1191 (2003)							
	20.	Becher, B., et al., The Journal of Clinical Investigation – 110(4):493-497 (2002)								
	21.	Burchill, M.A., et al., Infection and Immunity – 71(6):3437-3442 (2003)								
	22.	Bush, K.A., et al., Arthritis & Rheumatism – 46(2):802-805 (2002)								
	23.	Constantinescu, C.S., et al., The Journal of Immunology – 161:5097-5104 (1998)								
	24.	Cua, D.J., et al., Letters to Nature – 421:744-748 (2003)								
	25.	Dubowchik, G.M., et al., Pharmacology & Therapeutics – 83:67-123 (1999)								
··	26. 27	Fossiez, F., et al., J. Exp. Med. – <u>183</u> :2593-2603 (1996)								
	27. 28.	Goodin, D.S., et al., Neurology – <u>58</u> :169-178 (2001) Haak, S., et al., The Journal of Clinical Investigation – <u>119(1)</u> :61-69 (2009)								
	29.	Jonker, M., et al., Human Immunology – 32:31-40 (1991)								
	30.	 	Joosten, L.A.B., et al., The Journal of Immunology – 159:4094-4102 (1997)							
	31.		Jovanovic, D.V., et al., The Journal of Immunology – 160:3513-3521 (1998)							
	32.									

EXAMINER:	DATE CONSIDERED:			
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in				

conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

F	orm PTO-1449	Attorney's Docket No.	Application Serial No. 10/617,573		
· INFORMATION	DIOCI COURT OT ATEMENT	GNE-0290.041	10/017,575		
INFORMATION	DISCLOSURE STATEMENT	Applicant(s) Ellen FILVAROFF, et al.			
		Filing Date:	Group Art Unit:		
(use sever	ral sheets if necessary)	JULY 11, 2003	1646		
	Kuestner, R.E., et al., The Journal of Ir				
	Lock, C., et al., Nature Medicine – 8(5)				
	Lubberts, E., et al., The Journal of Imn				
	Matusevicius, D., et al., Multiple Sclero				
	Nakae, S., et al., Immunity – <u>17</u> :375-38				
	Nakae, S., et al., The Journal of Immur				
	Okuda, Y., et al., Journal of Neuroimm				
	Ozenci, V., et al., Multiple Sclerosis – 8:396-404 (2002)				
	Singh, V.K., et al., Immunologic Research - 20:147-161 (1999)				
	Tarner, I.H., et al., Current Opinion in I				
\	Tompkins, S.M., et al., Nature Medicin				
	Van Kooten, C., et al., J Am Soc Nephi				
	Wiendl, H., et al., Biodrugs – <u>16(3)</u> :183 Witowski, J., et al., The Journal of Imn		·		
	Yao, Z., et al., Immunity – <u>3</u> :811-821 (1995) Yazaki, P.J., et al., Protein Engineering, Design & Selection – <u>17(5)</u> :481-489 (2004)				
	Zhang, G-X., et al., The Journal of Imm				
10.	ending, o x., ot an, the country of min	110.2100 2100 (2000)			
	•	,			

EXAMINER:	DATE CONSIDERED:			
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in				

conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).